the two NK trials are investigator sponsored. CHM had a token financial contribution, which has already been made.
the CLTX Glioblastoma trial is currently paused. Will be resumed with an AU trial site. Expecting non dilutionary funding for the first few patients.
so that only leaves us with the CDH17 trial, which is currently enrolling up to 15 paitents in a dose escalation. CEO said that we may be able to start the phase 2 expansion for certain indications before enrolling all 15 patients.
Any strong efficacy signals, across any of these trials should result in a major rerating of the company. So we can raise capital at a higher SP resulting in less dilution.
Add to My Watchlist
What is My Watchlist?
